Late toxicity and quality of life from GETUG-AFU 22 study: A randomized phase II trial comparing 6 months of degarelix in combination with radiotherapy to radiotherapy alone for patients with detectable PSA after radical prostatectomy
| Autor: | Gilles Créhange, Laurent Salomon, E. Meyer, Ali Hasbini, Philippe Fourneret, G. De Laroche, S. Pelissier, P. Rochin, I. Latorzeff, Stéphane Supiot, Hadji Hamidou, E. Gross, A. Benyoucef, Elisabeth Deniaud-Alexandre, Julien Fraisse, Lysian Cartier, Edouard Lagneau, Stéphane Guerif, P. Pommier, Paul Sargos |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Prostatectomy business.industry Urology medicine.medical_treatment Radiotherapy alone lcsh:Diseases of the genitourinary system. Urology lcsh:RC870-923 lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens lcsh:RC254-282 Late toxicity Radiation therapy chemistry.chemical_compound Quality of life chemistry medicine Degarelix business |
| Zdroj: | European Urology Open Science, Vol 19, Iss, Pp e1398-e1399 (2020) |
| ISSN: | 2666-1683 |
| DOI: | 10.1016/s2666-1683(20)33522-9 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|